盘前大跌28%!诺和诺德司美格鲁肽升级版减重数据不及预期

澎湃新闻
20 Dec 2024

诺和诺德公布了司美格鲁肽合剂产品的积极减重研究数据,但由于不及此前市场预期,美股盘前股价大跌,而其竞争对手美国礼来公司盘前上涨明显。  12月20日,诺和诺德公布了一项名为REDEFINE 1的三期临床试验的主要结果。在评估所有人都坚持治疗的治疗效果时,使用 CagriSema 治疗的患者在68周后体重减轻了 22.7%,使用cagrilintide 2.4 mg的患者体重减轻了 11.8%,使用...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10